Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With ESR1-Mutated Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer?

被引：1
|
作者：
Okeya, Aoba [1 ]
Shimomura, Akihiko [2 ]
Kitagawa, Dai [1 ]
Shimizu, Chikako [2 ]
机构：
[1] Natl Ctr Global Hlth & Med, Dept Breast Surg Oncol, Tokyo, Japan
[2] Natl Ctr Global Hlth & Med, Dept Breast & Med Oncol, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 28期
关键词：
ESR1; MUTATIONS;
D O I：
10.1200/JCO.24.00992
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Efficacy of Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Fatima, Eeshal
    Altaf, Faryal
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (11): : 526 - 534
  • [42] Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
    Brufsky, Adam M.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2015, 9 : 137 - 147
  • [43] Expanding Treatment Arsenal for Oestrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
    Sze, H.
    HONG KONG JOURNAL OF RADIOLOGY, 2019, 22 (02): : 86 - 97
  • [44] Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
    Omori, Yukie
    Enatsu, Sotaro
    Cai, Zhihong
    Ishiguro, Hiroshi
    BREAST CANCER, 2019, 26 (05) : 652 - 662
  • [45] Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2
    Gelmon, Karen
    Walshe, Janice M.
    Mahtani, Reshma
    Joy, Anil A.
    Karuturi, Meghan
    Neven, Patrick
    Lu, Dongrui Ray
    Kim, Sindy
    Schnell, Patrick
    Bananis, Eustratios
    Schwartzberg, Lee
    BREAST, 2021, 59 : 321 - 326
  • [46] Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
    Yukie Omori
    Sotaro Enatsu
    Zhihong Cai
    Hiroshi Ishiguro
    Breast Cancer, 2019, 26 : 652 - 662
  • [47] Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer
    Tomiguchi, Mai
    Yamamoto, Yutaka
    Yamamoto-Ibusuki, Mutsuko
    Goto-Yamaguchi, Lisa
    Fujiki, Yoshitaka
    Fujiwara, Saori
    Sueta, Aiko
    Hayashi, Mitsuhiro
    Takeshita, Takashi
    Inao, Touko
    Iwase, Hirotaka
    CANCER SCIENCE, 2016, 107 (04) : 491 - 498
  • [48] Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial (vol 40, 3246, 2022)
    Bidard
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (23) : 3962 - 3962
  • [49] Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer
    Kurozumi, Sasagu
    Yamaguchi, Yuri
    Matsumoto, Hiroshi
    Inoue, Kenichi
    Kurosumi, Masafumi
    Oyama, Tetsunari
    Horiguchi, Jun
    Fujii, Takaaki
    Shirabe, Ken
    MEDICAL MOLECULAR MORPHOLOGY, 2019, 52 (02) : 90 - 98
  • [50] Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer
    Sasagu Kurozumi
    Yuri Yamaguchi
    Hiroshi Matsumoto
    Kenichi Inoue
    Masafumi Kurosumi
    Tetsunari Oyama
    Jun Horiguchi
    Takaaki Fujii
    Ken Shirabe
    Medical Molecular Morphology, 2019, 52 : 90 - 98
12345